Loading
Obrixtamig is an antibody with two arms: one grabs DLL3, a protein on the surface of most neuroendocrine carcinomas, and the other grabs a T cell, pulling the killer cell onto the cancer. It is in a phase 3 trial for neuroendocrine carcinomas outside the lung.
Obrixtamig (BI 764532) is Boehringer Ingelheim's DLL3-directed T-cell engager, a class established by tarlatamab in small-cell lung cancer. DLL3 is expressed on the surface of most small-cell lung cancers and extrapulmonary neuroendocrine carcinomas but almost no normal adult tissue. It is given intravenously with step-up dosing to limit cytokine release syndrome.
The phase 2 DAREON-5 trial reported responses in DLL3-positive small-cell lung cancer and extrapulmonary neuroendocrine carcinoma, and the phase 3 DAREON-NEC-1 trial is testing obrixtamig with carboplatin and etoposide first line in DLL3-positive extrapulmonary neuroendocrine carcinoma, the first phase 3 dedicated to that disease. The extrapulmonary neuroendocrine carcinoma page names it with peluntamig and ZG006 among the DLL3 engagers in trials.
1.One arm of Obrixtamig binds DLL3 on the cancer cell.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Obrixtamig" OR ABSTRACT:"Obrixtamig" OR TITLE:"BI 764532" OR ABSTRACT:"BI 764532" OR TITLE:"BI-764532" OR ABSTRACT:"BI-764532") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Obrixtamig, not a curated reading list.
Shares Boehringer Ingelheim and the tag subtype-drugs-wave.
Shares Tarlatamab, Bispecific antibodies, T-cell engagers (bispecific).
Shares DLL3, CD3, T-cell engagers (bispecific).
Shares Tarlatamab, Bispecific antibodies, T-cell engagers (bispecific).
Shares Tarlatamab, Bispecific antibodies, T-cell engagers (bispecific).
Shares Tarlatamab, Bispecific antibodies, T-cell engagers (bispecific).
Shares CD3, Bispecific antibodies, T-cell engagers (bispecific).
Shares Tarlatamab, Bispecific antibodies, T-cell engagers (bispecific).